apatinib and Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma

Acute lymphoblastic leukemia (ALL) is a clonal malignant disorder characterized by an uncontrolled proliferation of immature B or T lymphocytes. Extensive studies have suggested an involvement of angiogenesis signaling in ALL progression and resistance to treatment. Thus, targeting angiogenesis with anti-angiogenic drugs may be a promising approach for ALL treatment. In this study, we investigated the effectiveness of Apatinib, a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2 in ALL cells.. ALL cell lines were treated with different concentration of Apatinib and then CCK8 assay, flow cytometry were used to determine the IC. Our study indicates that Apatinib exerts its anti-leukemia effect by inducing apoptosis through suppressing the VEGFR2 signaling pathway, supporting a potential role for Apatinib in the treatment of ALL.

Topics: Adolescent; Adult; Aged; Animals; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Disease Progression; Down-Regulation; Female; Humans; Leukocytes, Mononuclear; Male; Mice; Middle Aged; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Signal Transduction; T-Lymphocytes; Time Factors; Xenograft Model Antitumor Assays; Young Adult